Insulin glargine
(Redirected from Toujeo)
Insulin Glargine[edit | edit source]
Insulin Glargine, commonly known under the brand name Lantus, is a long-acting insulin analog used to control blood sugar levels in patients with diabetes. This laboratory-made hormone is designed to provide more consistent blood sugar control compared to regular insulin.
Overview[edit | edit source]
Insulin Glargine is a recombinant form of insulin, used primarily for the management of Type 1 and Type 2 diabetes. It helps in regulating the metabolism of carbohydrates, fats, and proteins by promoting the absorption of glucose from the blood into liver, fat, and skeletal muscle cells.
Chemical Structure and Function[edit | edit source]
Insulin Glargine differs from human insulin in its amino acid sequence, which results in a lower solubility at physiological pH. This feature allows for a slower and more predictable absorption rate, ensuring a consistent insulin level for a longer period.
Clinical Use[edit | edit source]
Indications[edit | edit source]
- Management of Type 1 diabetes
- Management of Type 2 diabetes, particularly in cases where blood sugar is not adequately controlled by oral antidiabetic drugs
Administration[edit | edit source]
- Administered via subcutaneous injection
- Typically used once daily, often at bedtime
Comparisons with Other Insulins[edit | edit source]
Compared to short-acting insulin, Insulin Glargine provides a more stable, peakless, and prolonged insulin release, reducing the risk of nocturnal hypoglycemia.
Side Effects and Precautions[edit | edit source]
While generally well-tolerated, Insulin Glargine may cause side effects such as:
- Hypoglycemia (low blood sugar)
- Injection site reactions
- Allergic reactions in rare cases
Patients should monitor blood sugar levels regularly and adjust the dose under medical supervision.
Pharmacological Classification[edit | edit source]
Insulin Glargine is classified as a long-acting insulin analog and falls under the category of therapeutic insulin.
Development and Approval[edit | edit source]
Developed by Sanofi-Aventis, Insulin Glargine was first approved for medical use in the United States in 2000. Since then, it has become a widely used insulin analog worldwide.
References[edit | edit source]
Insulin glargine Resources | |
---|---|
|
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Kondreddy Naveen